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A b s t r a c t  
Ion exchange resins are commonly used for masking of drug objectionable taste. Our work aimed to 
study the effect of this complexation on the drug stability and bioavailability in rabbits. In this work, 
paracetamol and ibuprofen complexes with indion 204 were prepared; drug stability and 
bioavailability from the prepared complexes were studied and compared with that of the commonly 
used commercial tablets Tylenol and Motrin respectively. The clinical protocol and information about 
drugs were discussed with a group of healthy albino rabbits. The results showed that tmax of both 
drugs were kept constant at 1.5hrs and 2hrs without any change from the reference standards 
Tylenol and Motrin respectively. The calculated pharmacokinetic parameters Cpmax, AUC(0-24) and 
AUC(0-∞) respectively for paracetamol were 0.431µg/ml, 3.535µg.hr/ml and 3.756µg.hr/ml from the 
prepared complexes in comparison to 0.494µg/ml, 4.083µg.hr/ml, 4.198µg.hr/ml from Tylenol, and 
0.743µg/ml, 5.380µg.hr/ml, 5.559µg.hr/ml from the prepared ibuprofen complexes in comparison to 
0.803µg/ml, 6.272 µg.hr/ml, 6.432 µg.hr/ml from Motrin. The relative bioavailability of both drugs 
from the prepared complexes were calculated using Tylenol and Motrin as reference standards and 
the 90 % confidence intervals of the geometric mean values for the test/reference ratios for Cpmax, 
AUC (0-24) and AUC (0-∞) were within the bioequivalence acceptance range of 80–125 % according to 
the European Guideline. Statistical analysis (ANOVA) indicated a significance difference between 
the calculated pharmacokinetic parameters for both drugs. From these results we can conclude that 
indion complexation of drugs significantly affects their pharmacokinetics and retards their 
bioavailability. 
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Introduction 
The bitter nature of many orally administered drugs creates an 
objectionable feeling in the mouth. This results in patient 
incompliance to these medicines especially in children and elderly, 
thereby retarding the effectiveness of the pharmacotherapy [1]. 
The American Academy of Pediatrics estimates that compliance in 
children is as low as 53%, indicating that children frequently fail to 
take medications properly. Noncompliance can cause extended 
symptoms, excessive doctor visits and may be hospitalizations, 
relapses, additional medications may be prescribed, increased 
healthcare cost and in cases of infectious diseases resistant 
organisms may be developed [2]. 
One of the popular approaches in the taste masking of bitter drugs 
is based on Ion exchange resins; which is one of the most exciting 
technologies for the pediatric industry and can be described as an 
ideal process where the taste of bitter medicament can be 
successfully masked. [3, 4] 
Ion exchange resins are solid water insoluble high molecular 
weight polyelectrolytes that can exchange their mobile ions of 
equal charge with the surrounding medium reversibly. Typically, 
the ionized drug form and the ion-exchange resin form a stable 
complex and the drug be unavailable for taste sensation hence 
taste masking occur. The average pH of 6.7 and cation 
concentration in the saliva (about 40meq/L) are not able to break 
the drug resin complex and this complex prevents the drug release 
in the saliva, thus resulting in absolute taste masking with no after 
taste. [3] Low gastric pH, increased ionic concentration of the GIT, 
larger volume of the release media and/or increased gastric 
residence time all cause drug release from the ion-exchange resin 
into the surrounding media and is, thus, be available for absorption 
[4] paracetamol and ibuprofen are used as drug models for this 
application.  
Paracetamol (which in some countries is called acetaminophen) 
has been safely used for many years to help with mild to moderate 
pain and fever for babies over 1 month of age and up to adult age. 
paracetamol must be given with caution to a sick child, for too long 
time otherwise, it may be harmful. Ibuprofen is a newer drug than 
paracetamol to relief fever and mild to moderate pain in children 
and adults, but not suitable for children under 3 months of age. [5] 
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Acetaminophen is an odorless, slightly bitter taste white crystalline 
powder. It is soluble in organic solvents but slightly soluble in 
water. It's pH range is 5.5 - 6.5 based on saturated aqueous 
solution. It, chemically N-(4-Hydroxyphenyl) acetamide. 
Acetaminophen is a nonprescription analgesic and antipyretic drug 
similar to aspirin. But acetaminophen is not an NSAID 
(Nonsteroidal Anti-inflammatory Drug) as it doesn't participate in 
the inflammatory response as it cannot inhibit cyclooxygenases in 
the presence of peroxides. Paracetamol has almost no adverse 
effects on the stomach or esophagus. [6] 
Following oral administration it is rapidly absorbed from the 
gastrointestinal tract, and depending on drug dose the systemic 
bioavailability ranging from 70 to 90%. Its rate of oral absorption is 
predominantly dependent on the rate of gastric emptying. 
Paracetamol is effectively absorbed from the rectum. It rapidly 
distributes throughout most tissues and fluids with volume of 
distribution of approximately 0.9L/kg. 10 to 20% of the drug is 
bound to red blood cells. Paracetamol is extensively metabolized, 
mainly in the liver as sulphate and glucuronide conjugates. [7] 
Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), is a 
propionic acid group member. It is a white to off-white crystalline 
powder that melts at about 74° to 77°C. It is practically insoluble in 
water (<0.1 mg/ml), but readily soluble in organic solvents. 
Ibuprofen has a pKa of 4.43±0.03. It is chemically  (±)-2-(p-isobutyl 
phenyl) propionic acid. Its molecular formula is C13H1802. [6] 
Ibuprofen works by reducing hormones of inflammation and pain in 
the body as analgesic and to relief of symptoms of arthritis, 
dysmenorrhea, fever. [8] 
Its mode of action, like other NSAIDs, is not clearly understood, but 
may be related to prostaglandin synthetase inhibition. In the body 
the [-]R-enantiomer of ibuprofen undergoes interconversion to the 
[+]S-form. The biological activities of ibuprofen are associated with 
the [+]S-enantiomer. Although ibuprofen is a non-selective 
cyclooxygenase (COX) inhibitor, its analgesic, antipyretic and anti-
inflammatory effects are achieved principally through COX-2 
inhibition. [9-11] 
Ibuprofen is absorbed from the gastro-intestinal tract and peak 
plasma concentrations are reached within about 1 to 2 hours after 
ingestion. Bioavailability is ≥ 80%. 99% of ibuprofen is bound to 
plasma proteins, 90% is transformed to 2 inactive metabolites and 
it has a plasma half-life of about 2 ± 0.5 hours. It is rapidly excreted 
in the urine mainly as metabolites and their conjugates. About 1% 
is excreted in urine as unchanged ibuprofen. Studies in febrile 
children have established the proportionality at doses of 5 and 10 
mg/kg of ibuprofen. Studies in adults have established the 
proportionality of ibuprofen at a single oral dose from 50 to 600 mg 
for total drug and up to 1200 mg for free drug [12] 
It is claimed that complexation of exchange resins with drugs for 
masking their objectionable taste not affect their bioavailability as 
these complexes are weak enough to break down by hydrochloric 
acid present in the stomach without neglicable effect on their 
bioavailability. [3] They also possess modifying release properties 
and commonly used for sustaining drug action. [13] This work aims 
to investigate the effect of indion complexation on the bioavailability 
and also the stability of drugs. Paracetamol and Ibuprofen were 
selected as drug models and indion 204 was selected as a resin 
model for this work. 
Materials and Methods 
Materials 
Ibuprofen and Paracetamol were received as gift samples from El-
Nasr Pharmaceutical Chemical Co., Abo-Zaabal, Cairo, Egypt. 
Indion 204 was received as gift samples from EPCI, Beni-Suief, 
Egypt.  Propyl paraben (Sigma Chemical Co., USA). Methanol and 
Acetonitrile (HPLC grade, Romil Chemical Co., England).  
Children  s Tylenol Meltaways (80mg paracetamol chewable 
tablets, McNeil Consumer Healthcare, USA). Motrin Junior 
Strength (100mg ibuprofen chewable tablets, McNeil Consumer 
Healthcare, USA). All other solvents and chemicals used 
throughout the study are official and of analytical grades and were 
used as received. 
Methods 
Preparation of drug indion complexes 
Batches of drug resinate mixtures were prepared at optimized 
conditions for maximum loading capacity [14]:    
For this purpose, adequate quantities of acid activated resin (indion 
204) were placed in different beakers containing adequate 
quantities of deionized water and allowed to swell for 30 min. 
Paracetamol and Ibuprofen were separately added to each beaker 
at 1:3 drug: resin ratio and stirred using a magnetic stirrer for six 
hours at 80ºC. The mixtures were filtered and residues were 
washed with adequate quantities of deionized water and drug 
content was determined as follows: 
Accurately weighed amounts of the prepared resinate complexes 
equivalent to 10 mg of each drug were separately added to 100 ml 
of 0.1 N HCl and stirred at 100 rpm for 1 h, till the entire drug 
leached out. The solutions were filtered through a filter paper No. 
41 and the drug content was determined spectrophotometrically at 
λmax 243nm and 222nm for paracetamol and ibuprofen 
respectively after suitable dilution. [15] 
Determination of drug release rate 
Accurately weighed amounts of the prepared drug resinate 
complexes equivalent to the normal dose of each drug as well as 
crushed commercial Motrin and Tylenol tablets were subjected to 
in-vitro dissolution studies using USP dissolution apparatus II at 
100 rpm with temperature of 37±0.5ºC and 900 ml dissolution 
medium (0.1 N HCl for paracetamol and phosphate buffer pH 7.2 
for ibuprofen). Aliquots of 5 ml were withdrawn at specific pre-
determined time interval of 5, 10, 15, 20, 30, and 45 minutes with 
replacement. The amount of the drug in each sample was 
measured spectrophotometrically at λmax 243nm and 222nm for 
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paracetamol and ibuprofen respectively. The mean of six 
determinations was considered. 
The effect of excipients on the release rate of both drugs from the 
commercial tablet mixture Tylenol and Motrin was considered. 
Where the dissolution rate of plain drugs paracetamol and 
ibuprofen under the experimental conditions was calculated and 
compared.Bioequivalence was assessed based on comparison of 
dissolution parameters like t50 (50%dissolution) and calculation of 
similarity factor (f2). The similarity factor, f2 used as the 
mathematical model for comparing the bioequivalence of the nine 
brands was calculated using the following formula: 
 
 
Where, f2 = Similarity factor; n = Number of time points; R (t) = 
Mean percent drug dissolved e.g. a reference product; T (t) = Mean 
percent drug dissolved of e.g. a test product. Not more than one 
mean value of >85% dissolved for each formulation. An f2 value 
between 50 and 100 suggests that the two dissolution profiles are 
similar. [16] 
Stability study 
Accurately weighed amounts of the prepared complexes of 
paracetamol resinate and ibuprofen resinate equivalent to the 
normal dose of each drug as well as the commercial forms Tylenol 
and Motrin were separately packed in transparent glass jars with 
plastic closures and subjected to stress accelerated stability 
studies. Jars were stored at different temperatures (namely: 40ºC ± 
0.5, 50ºC ± 0.5 and 60ºC ± 0.5) for a time period of six months. 
The humidity was fixed at 75% relative humidity at all 
temperatures. Samples of the prepared complexes of paracetamol 
resinate and ibuprofen resinate as well as the commercial forms 
Tylenol and Motrin were withdrawn, at specified pre-determined 
time intervals (namely: 1, 2, 3, 4, 5 and 6 months) during the 
storage period and evaluated as follows:  
Determination of drug content: (fresh and stored) 
Samples of paracetamol resinate and ibuprofen resinate as well as 
the commercial forms Tylenol and Motrin were separately 
transferred to a 100-ml volumetric flask, and the volume was 
completed with methanol (HPLC grade). The solution was filtered, 
the first 20 ml were rejected then 1 ml of the filtrate was diluted to 
100 ml by methanol. One ml aliquot of the prepared solution was 
transferred to 10-ml volumetric flask, 0.5 ml internal standard 
(propyl paraben) was added and the volume was completed with 
methanol. 
The unknown concentration of ibuprofen in each chewable tablet 
was calculated as follows: 
Q = (R/A ± B) x dilution factor 
Where, Q is the drug concentration, R is the peak area ratio 
(drug/internal standard), A is the slope of the calibration curve and 
B is the Y-intercept. 
Kinetic analysis of data and expiry date determination 
The stability data of drugs from the prepared indion complexes was 
kinetically analyzed by means of a personal computer using linear 
regression according to zero- and first-order kinetic models; the 
correlation coefficient (r) was determined. Using Garett-Karper 
method; the decomposition rate constant (K) was calculated 
according to the determined order at each of the three 
temperatures. The (K) values at different temperatures were 
plotted against the reciprocal of the corresponding absolute 
temperatures on the logarithmic scale according to the Arrhenius 
plot for the determination of the predictive shelf life at room 
temperature. 
In-vivo evaluation studies 
Animals: 
The clinical protocol and information about drugs were discussed 
with a group of healthy rabbits. Fifteen male albino rabbits 
weighing 2.5-3.0 kg, taking the same diet along the time of the 
study, fasted overnight before drug administration and allowed free 
access to water. They are used in this study to determine the 
bioavailability of drugs from the prepared indion complexes as well 
as assuring the bioequivalence of these prepared complexes in 
comparison to the commercial chewable tablets; Motrin Junior 
Strength and Tylenol.  The animal dose of drugs was calculated 
with reference to Paget and Barnes table which relates the animal 
dose to the human daily dose. [17] 
Study design 
The study was performed on three phases according to a 
randomized crossover design. A washout period of one week 
separated between the phases. At the beginning of the study a 
control sample of 2 ml blood was withdrawn from each rabbit 
before drug administration. 
Accurately weighed amounts of the prepared drug resinate 
complexes of each drug as well as crushed commercial Motrin and 
Tylenol tablets equivalent to the calculated animal dose were 
suspended in minimal volume of water and administered to rabbits 
by the aid of insulin syringe. Suspensions of both plain 
paracetamol and ibuprofen equivalent to the calculated animal 
doses were also prepared and administered to rabbits as control to 
detect the excipients effect on the bioavailability of both drugs from 
the commercial tablet mixtures Tylenol and Motrin. Blood samples 
were obtained at specified pre-determined time intervals (namely 0, 
0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24) hours post dose. All the 
samples were collected in heparinized tubes and immediately 
centrifuged at 3000 rpm for 15 minutes and the plasma was frozen 
and stored at –20ºC until the analysis. 
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Analytical procedure for determination of drug in plasma 
Simple and sensitive HPLC methods for the determination of drug 
in plasma were used. In case of ibuprofen; the mobile phase 
composed of acetonitrile: methanol: phosphate buffer pH 3.2 
(50:10:40 v/v) and in case of paracetamol; the mobile phase 
composed of acetonitrile: methanol: phosphate buffer pH 6.3 
(17.5:17.5:65 v/v). The mobile phase was filtered through 0.45 µm 
pore size filter. The flow rate was 1 ml/min in all cases, the 
detection wavelength was 264nm in ibuprofen and 254nm in 
paracetamol and the sensitivity was set at 0.0001 AUFS. After 
extraction from plasma, the drug was chromatographed on a C-18 
reverse phase column. 
Pharmacokinetics parameters (namely Cpmax, Tmax, AUC(0-24), 
AUC(0-∞), t1/2, and K) for both drugs from the prepared indion 
complexes and commercial Tylenol and Motrin formulae were 
calculated and compared. The Relative bioavailability of drugs was 
also calculated using the commercial formulae as reference 
standards.  
Pharmacokinetic Parameters and Statistical Analysis of 
Data 
The calculated pharmacokinetic parameter including Cpmax, Tmax, 
[AUC] 0-24, [AUC] 0-∞, t1/2 and K was subjected to statistical analysis 
of variance (ANOVA) according to student t-test. P < 0.05 was 
considered statistically significant in all calculations. For [AUC] and 
Cpmax, a 90 % parametric confidence interval was defined for the 
ratio test/reference using the residual variability obtained from the 
ANOVA. According to the european guidance [18]; Bioequivalence 
assessment was based on a predefined acceptance criterion of 
80–125 % for the ratio test/reference and its 90 % confidence 
interval for the log-transformed data of AUC(0–24) , AUC(0–∞) and 
Cpmax. 
Results 
Drug release rate 
Release rate of Paracetamol and Ibuprofen from the prepared 
resinate complexes in comparison to the commercial formulae 
Tylenol and Motrin against the dissolution profiles of plain drugs 
are shown in figures 1and 2. Histograms of the half lives of 
dissolution of both drugs are illustrated in figure 3. It is clear from 
these results that there was a significant delay in the drug release 
rate of both drugs; where the percentage of paracetamol released 
after 45 minutes from resinate complex reached 96.13% with half 
life of 8.15 minutes in comparison to 99.25% from Tylenol with half 
life of 6.72 minutes; and the percentage of Ibuprofen released also 
after 45 minutes from its resinate complex reached 97.21% with 
half life of 7.78 minutes in comparison to 99.57% with half life of 
6.02 minutes from Motrin tablets. The results also indicate that the 
effect of excipients in both Tylenol and Motrin tablet mixtures on 
the dissolution rates of both drugs was neglicable. The calculated 
dissolution parameters for comparison (similarity factors, f2 and T50) 
for paracetamol and ibuprofen from the prepared resinate 
complexes and commercial forms Tylenol and Motrin is shown in 
Table 1. All results still fall within the acceptable range of 50–100. 
[16] 
Stability study 
Figure 4 and 5 shows histograms of the percentage of drug 
remained after storage at different conditions (namely 40ºC±0.5, 
50ºC±0.5 and 60ºC±0.5) for a time period of six months. the 
percentage drug remained in all cases was higher than 90% 
without any considerable difference in drug content between 
resinate complexes and commercial forms of both drugs at all 
storage conditions, where the percentage paracetamol remained 
after six months was 93.97, 93.65, and 91.24% in Tylenol in 
comparison to 93.51, 93.34, and 90.64% in resinate complex; and 
the percentage Ibuprofen remained was 94.83, 92.84, and 91.15 in 
Motrin in comparison to 93.78, 91.87, and 90.53% in resinate 
complex when stored at 40ºC±0.5, 50ºC±0.5 and 60ºC±0.5 
respectively. 
Kinetic analysis of the stability data of both drugs from the stored 
formulae (commercial and resinate complexes) revealed that; the 
degradation followed first-order kinetics at all storage conditions. 
The predictive shelf life (t90) was calculated for Paracetamol and 
was found to be 1.10 and 1.05 years for resinate complex and 
Tylenol respectively; while the predictive shelf life (t90) for Ibuprofen 
was found to be 1.09 and 1.12 years for resinate complex and 
Motrin respectively; The results are shown in Tables 2 and 3. 
In-vivo evaluation studies: 
The bioavailability of Paracetamol and Ibuprofen from their 
corresponding tested commercial chewable tablet formulae Tylenol 
and Motrin respectively in comparison to the prepared resinate 
complexes was determined using plasma data obtained from  
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Figure 1: Dissolution profiles of paracetamol. 
     
Figure 2: Dissolution profiles of ibuprofen. 
 
                        Table 1: Dissolution data of paracetamol and ibuprofen. 
 
Drug PARACETAMOL IBUPROFEN 
Formula Control Tylenol Resinate Control Motrin Resinate 
T50 (min) 6.64 6.72 8.15 5.88 6.02 7.78 
F2  51.293  51.494 
 
 
Table 2: Kinetic data of accelerated stability testing of paracetamol after storage at different temperatures for 
six months. 
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t90 
at 25ºC 
(years) 
t1/2 
at 25ºC 
(years) 
K25 
(months-1) 
K Values at the Following Temperatures (ºK) 
on Logarithmic Scale 
333ºK 323ºK 313ºK Temp. (K) 
1.10 7.29 0.00792 0.0161 0.0138 0.0115 Resinate 
1.05 6.94 0.00831 0.0138 0.0115 0.0115 Tylenol 
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Table 3: Kinetic data of accelerated stability testing of ibuprofen after storage at different temperatures for 
six months. 
 
 
 
 
 
 
 
 
 
 
 
Table 4: The mean pharmacokinetic parameters of paracetamol following the oral administration to rabbits. 
 
Parameters 
Control Resinate Tylenol 
Tmax (hr) 1.5±0.00 1.5±0.00 1.5±0.00 
Cpmax (µg/ml) 0.475±0.07 0.431±0.08 0.494±0.05 
AUC(0-24) (µg.hr/ml) 3.977±0.06 3.535±0.09 4.083±0.06 
AUC(0-∞) (µg.hr/ml) 4.139±0.07 3.756±0.06 4.198±0.03 
t1/2 (hr) 3.21±0.03 3.89±0.07 3.18±0.05 
K (hr-1) 
0.228±0.09 0.179±0.02 0.238±0.12 
 
 
Table 5: The mean pharmacokinetic parameters of ibuprofen following the oral administration to rabbits. 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Bioequivalence assessment summary of paracetamol following the oral administration of its resinate 
and commercial Tylenol formulae to rabbits. 
 
Parameter 
Paracetamol Formulae 
T/R Ratio (%) 90% CI (%) 
Cpmax 87.25 86.44–88.21 
AUC (0-24) 86.59 85.16-87.12 
AUC (0-∞) 89.471 88.41-90.35 
 
 
 
 
 
t90 
at 25ºC 
(years) 
t1/2 
at 25ºC 
(years) 
K25 
(months-1) 
K Values at the Following Temperatures (ºK) 
on Logarithmic Scale 
333ºK 323ºK 313ºK Temp. (K) 
1.09 7.21 0.008002 0.0138 0.0138 0.0115 Resinate 
1.12 7.39 0.0078095 0.0115 0.0115 0.0092 Motrin 
Parameters 
Control Resinate Motrin 
Tmax (hr) 2.0±0.00 2.0±0.00 2.0±0.00 
Cpmax (µg/ml) 0.797±0.08 0.743±0.03 0.803±0.02 
AUC(0-24) (µg.hr/ml) 6.069±0.02 5.380±0.09 6.272±0.05 
AUC(0-∞) (µg.hr/ml) 6.268±0.05 5.559±0.08 6.432±0.06 
t1/2 (hr) 1.68±0.04 2.08±0.01 1.79±0.03 
K (hr-1) 
0.378±0.07 0.334±0.02 0.391±0.01 
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Table 6: Bioequivalence assessment summary of ibuprofen following the oral administration of its resinate 
and commercial Motrin formulae to rabbits. 
 
Parameter 
Ibuprofen Formulae 
T/R Ratio (%) 90% CI (%) 
Cpmax 92.53 89.45-96.15 
AUC (0-24) 85.78 85.08-86.36 
AUC (0-∞) 88.63 86.38-90.88 
 
 
Figure 3: Histogram of t1/2 values of the dissolution of paracetamol and ibuprofen 
 
 
 
Figure 4: Histogram of the percentage of paracetamol remained after storage at 
different conditions for six months. 
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Figure 5: Histogram of the percentage of ibuprofen remained after storage at different conditions for six months. 
 
 
 
 
                Figure 6: Calibration curve of paracetamol in plasma at λ max  254 nm using HPLC method. 
 
 
 
              Figure 7: Calibration curve of ibuprofen in plasma at λ max  264 using HPLC method. 
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Figure 8: Mean plasma concentration-time curves of paracetamol following the oral administration to rabbits. 
 
 
Figure 9: Mean plasma concentration-time curves of ibuprofen following the oral administration to rabbits. 
 
 
fifteen male albino rabbits. The calculated drug doses of each 
formula was administered orally to the rabbits and the drug plasma 
concentrations were determined by an accurate and sensitive 
HPLC assay method. 
HPLC chromatograms in plasma, in the presence of propyl 
paraben as internal standard indicated that, the retention times of 
paracetamol and the internal standard were 3.24 and 3.99 minutes 
respectively, while the retention times of the ibuprofen and the 
internal standard were 3.12 and 3.95 minutes respectively. The 
percentage recovery was calculated to indicate the suitability of the 
assay, the mean percentage recovery of paracetamol was 99.84% 
with coefficient of variation of 2.98% and of ibuprofen was 99.90% 
with coefficient of variation of  2.47%.  
Figures 6 and 7 show the plasma calibration curve of paracetamol 
and ibuprofen respectively in the range of 1-10 µg/ml. The 
equations of linear regression of the curves were Y = 0.265 X + 
0.005 and Y = 0.274 X + 0.034; where, X is the drug concentration 
in µg/ml and Y is the ratio of the area of drug peak to the area of 
internal standard peak. The correlation coefficient were 0.999 and 
0.997 which suggests the accuracy of the assay. 
Figure 8 shows the mean plasma concentration-time curves after 
the oral administration of the prepared Paracetamol-resinate 
complex and Tylenol chewable tablet formula against plain 
paracetamol suspension as a control to the rabbits and the mean 
pharmacokinetic parameter of the drug from both formulae and 
plain drug suspension were listed in Table 4, from which it was 
found that, the time required to reach the peak plasma 
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were obtained for Ibuprofen as shown in Table 5 and graphically 
illustrated in figure (9) where the time required to reach the peak 
plasma concentration (Tmax) was kept constant at 2 hours in all 
tested samples.  
Regarding the drug maximum plasma concentration following oral 
administration of both drugs; results in Tables 4 and 5 and figures 
8 and 9 show that Paracetamol and Ibuprofen reached higher 
plasma concentrations from Tylenol and Motrin formulae 
respectively than from resinate complexes where the maximum 
plasma concentration of Paracetamol and Ibuprofen was 
0.494µg/ml and 0.803µg/ml from Tylenol and Motrin in comparison 
to 0.431µg/ml and 0.743µg/ml from their resinate complexes  
respectively. 
Area under the plasma concentration-time curve [AUC] of 
Paracetamol and Ibuprofen from commercial forms Tylenol and 
Motrin in comparison to the prepared resinate complexes is also 
listed in Tables 4 and 5. from the results we can note that drug-
resinate complexation caused lowering of the total amount of drug 
absorbed as indicated by [AUC] values; where Paracetamol 
showed AUC(0-∞) values of 3.756 µg.hr/ml and 4.198 µg.hr/ml for 
resinate complex and Tylenol respectively while Ibuprofen showed 
AUC(0-∞) values of 5.559 µg.hr/ml and 6.432 µg.hr/ml for resinate 
complex and Motrin respectively. 
Results of vivo study as listed in Tables 4 and 5 and illustrated in 
figures 8 and 9 indicate that the effect of excipients in both Tylenol 
and Motrin tablet mixtures on pharmacokinetic parameters and 
bioavailability of both drugs was neglicable. Where the plasma 
concentration time curves of both drugs from Tylenol and Motrin 
tablet mixtures were almost identical and about to superimpose 
with that of plain drug suspensions. 
Two-way analysis of variance (ANOVA) test was performed in 
order to determine the significance of the detected difference 
between the calculated pharmacokinetic parameters  (namely: 
Cpmax, T1/2,  AUC(0-24) and AUC(0-∞) of both drugs from the 
commercial formulae and their resinate complexes at probability 
level (α) equals 0.05. Results of variance analysis clearly detected a 
significant difference between all tested pharmacokinetic 
parameters at the specified probability level for both drugs. 
Finally; the percentage relative bioavailability of Paracetamol and 
Ibuprofen from the prepared resinate complexes was calculated 
using the commercial formulae (Tylenol and Motrin) respectively as 
reference standards and accepted to be bioequivalent. The 90 % 
confidence interval for the ratio of the logarithmically transformed 
values of primary variables [AUC(0–t), AUC(0-24) and Cpmax] laid 
between the predefined range of 80–125 %. [18] Results are 
presented in Tables 6 and 7 
Discussion 
Paracetamol and ibuprofen are non steroidal anti-inflammatory 
drugs that are commonly used in controlling fever and other 
inflammatory conditions in children. the problem of objectionable 
taste of  both drugs act as a great challenge for most formulators 
and greatly affects the physician choice during prescription. Solid 
oral formulations including orodispersible and chewable tablets 
taken a great consideration in recent experiments to overcome the 
problem of bad taste of  liquid formulations and difficulty of 
swallowing of conventional tablets so many taste masking 
techniques were applied for this purpose including loading onto 
ion-exchange resin. In this work our aim was to investigate the 
effect of this complexation on the bioavailability and stability of 
these drugs.  
The effect of indion drug complexation on the drug stability was 
neglicable where the percentage drug released in both formulae 
and expiry date of both drugs were almost the same.    
It is documented that drug release from these complexes is 
dependent mainly on the electrolyte concentration in the release 
media which in turn affects the absorption rate and extent and may 
sustain the drug release [3 and 13]; we correlated the drug release 
rate data of both drugs from the prepared resinate complexes with 
indion (a cationic exchange resin) with the calculated 
pharmacokinetic parameters. In case where > 85% of the drug is 
dissolved within 15 minutes, dissolution profiles are usually 
accepted as similar without further mathematical evaluation [16]; 
the dissolution profile of paracetamol and ibuprofen did not achieve 
these results so parameters like t50 and similarity factor (f2) derived 
from the dissolution profile were used as estimators for the 
bioavailability of both drugs [19], Our results showed that; drug 
indion complexation markedly affected the release rate where 
mainly the mean half life of dissolution rate was significantly 
prolonged and the calculated values of similarity factors for both 
drug was extremely law indicating poor similarity of dissolution 
profiles and hence poor bioequivalence between the prepared 
resinate complexes and commercial forms.  
To prove two or more drug products are bioequivalent, a similarity 
in the rate and extent to which the drug in dosage form become 
available for absorption need to be demonstrated based on the 
analysis of the calculated variance AUC and Cpmax are indicators 
of the extent of drug absorbed while the time for maximum drug 
concentration in plasma (Tmax) is an indicator of the absorption 
rate.    
Results of ANOVA test reflected a significant delay in the almost all 
pharmacokinetic parameters of both drugs; where the elimination 
half lives were prolonged and the maximum drug plasma 
concentrations were significantly lowered and finally the overall 
amount of absorbed drug as represented by the area under the 
plasma concentration time curves was decreased. 
The calculated relative bioavailability indicated that; despite this 
significant effect of indion complexation on pharmacokinetic 
parameters of both drugs and based upon 90 % confidence interval 
for the ratio of geometric means (test/reference) of logarithmically 
transformed AUC(0–24). AUC(0-∞) and Cpmax, they still bioequivalent 
as the 90 % confidence intervals for the ratio of AUC(0–24). AUC(0-∞) 
and Cpmax were within the acceptable FDA bioequivalence limits 
(85 to 125%).     
Conclusion 
Drug loading onto indion (as a cationic exchange resin model) 
significantly retarded the release rate of both drugs but the release 
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profile still follows first order kinetics. The stability of both drugs 
was not affected by resinate complexation. Despite the detected 
variance between the calculated pharmacokinetic parameters was 
statistically significant, The calculated percentage relative 
bioavailability of the logarithmically transformed values of primary 
variables [AUC(0–t), AUC(0-24  and Cpmax] was within accepted 
European limits at the predefined probability level and 90% 
confidence interval. This all laid to the final conclusion that indion 
complexation as a technique for masking of objectionable taste is 
accepted but we recommend it as inferior technique for taste 
masking due to the expected significant effect on drug 
bioavailability. 
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